Status: Not yet recruiting
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
This study aims to assess the safety profile of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms.
Participants needed: 18
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Liping DouUpdated: May 14, 2026
Eligibility criteria
Voluntary signing of informed consent by the subject or legally authorized repre... [+11]
Severe cardiac dysfunction with left ventricular ejection fraction (LVEF) < 50%. [+10]